Publications:

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Current Medicinal Chemistry

Shuttleworth, S J SJ; Silva, F A FA; Cecil, A R L AR; Tomassi, C D CD; Hill, T J TJ; Raynaud, F I FI; Clarke, P A PA; Workman, P P

Publication Date: 2011

Variant appearance in text: PIK3CA: L814C

PubMed Link: 21649578

Variant Present in the following documents:

• Main text

View BVdb publication page

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Oncotarget

Chappell, William H WH; Steelman, Linda S LS; Long, Jacquelyn M JM; Kempf, Ruth C RC; Abrams, Stephen L SL; Franklin, Richard A RA; Bäsecke, Jörg J; Stivala, Franca F; Donia, Marco M; Fagone, Paolo P; Malaponte, Graziella G; Mazzarino, Maria C MC; Nicoletti, Ferdinando F; Libra, Massimo M; Maksimovic-Ivanic, Danijela D; Mijatovic, Sanja S; Montalto, Giuseppe G; Cervello, Melchiorre M; Laidler, Piotr P; Milella, Michele M; Tafuri, Agostino A; Bonati, Antonio A; Evangelisti, Camilla C; Cocco, Lucio L; Martelli, Alberto M AM; McCubrey, James A JA

Publication Date: 2011-03

Variant appearance in text: PIK3CA: L814C

PubMed Link: 21411864

Variant Present in the following documents:

• Main text
• oncotarget-02-135.pdf

View BVdb publication page

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

Cancer Cell

Zunder, Eli R ER; Knight, Zachary A ZA; Houseman, Benjamin T BT; Apsel, Beth B; Shokat, Kevan M KM

Publication Date: 2008-08-12

Variant appearance in text: PI3K: L814C

PubMed Link: 18691552

Variant Present in the following documents:

• Main text

View BVdb publication page